Firms form Alzheimer's test deal:
This article was originally published in Clinica
Applied NeuroSolutions has linked up with fellow Illinois firm Nanosphere to develop a sensitive and specific early test for Alzheimer's disease. Nanosphere's Biobarcode technology for ultra-sensitive protein detection will be combined with Applied NeuroSolutions' biomarkers, which have been shown to be 85-95% accurate in detecting the disease. There are currently no US FDA-approved diagnostic tests for detecting Alzheimer's disease; it can only be confirmed post-mortem, Applied NeuroSolutions (Vernon Hills) and Nanosphere (Northbrook) noted.
You may also be interested in...
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
US FDA Will Need About A Week To Complete COVID Vaccine Assessment Following Advisory Cmte., CBER’s Marks Says
Timeline is the most pessimistic public projection to date, but still incredibly fast. Clinical trial patients on placebo could be contacted and offered the vaccine after an EUA is granted.